Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.17.7491

Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma  

Mansour, Sahar F (Pathology Department, Faculty of Medicine, Suez Canal University)
Atwa, Maha M (Pathology Department, Faculty of Medicine, Suez Canal University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.17, 2015 , pp. 7491-7496 More about this Journal
Abstract
Background: Biomarkers in breast neoplasms provide invaluable information regarding prognosis and help determining the optimal treatment. We investigated the possible correlation between cancer stem cell (CSC) markers (CD133, and ALDH1) in invasive ductal breast carcinomas with some clinicopathological parameters. Aim: To assess the correlation between expression of cancer stem cell (CSC) markers (CD133, and ALDH1) and clinicopathological parameters of invasive ductal breast carcinomas. Materials and Methods: Immunohistochemical analysis of CD133 and ALDH1 was performed on a series of 120 modified radical mastectomy (MRM) specimens diagnosed as invasive ductal breast carcinoma. Results: Expression of both CD133 and ALDH1 was significantly changed and related to tumor size, tumor stage (TNM), and lymph node metastasis. A negative correlation between CD133 and ALDH1 was found. Conclusions: Detecting the expression of CD133 and ALDH1 in invasive ductal breast carcinomas may be of help in more accurately predicting the aggressive properties and determining the optimal treatment.
Keywords
Breast carcinoma; cancer stem cell markers; CD133; ALDH1;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Alison MR, Guppy NJ, Lim SM, et al (2010). Finding cancer stem cells, are aldehyde dehydrogenases fit for purpose?. J Pathol, 222, 335-44.   DOI
2 Bertolini G, Roz L, Perego P, et al (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U.S.A, 106, 16281-6.   DOI
3 Bexell D, Gunnarsson S, Siesjo P, et al (2009). CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. International J Cancer, 125, 15-22.   DOI
4 Bozzi F, Conca E, Manenti G, et al (2011). High CD133 expression levels in gastrointestinal stromal tumors. Cytometry B Clin Cytom, 80, 238-47.
5 Charafe-Jauffret E, Ginestier C, Iovino F, et al (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res, 16, 45-55.   DOI
6 Clark MF, and Fuller M (2006). Stem cells and cancer, Two faces of eve. Cell, 124, 1111-5.   DOI
7 Clevers H (2011). The cancer stem cell, Premises, promises and challenges. Nat Med, 17, 313-9.   DOI
8 Deng S, Yang X, Lassus H, et al (2010). Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One, 5, 10277.   DOI
9 Di Bonito M, Collina F, Cantile M, et al (2012). Aberrant expression of cancer stem cells marker prominin-1 in low-grade tubulobular breast carcinoma, a correlative study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis. J Breast Cancer, 15, 15-23.   DOI
10 Douville J, Beaulieu R & Balicki D (2009). ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev, 18, 17-25.   DOI
11 Ferlay J, Soerjomataram I, Ervik M, et al (2013). Cancer Incidence and Mortality Worldwide (2013). IARC Cancer Base No. 11 Lyon, France, International Agency for Research on Cancer. GLOBOCAN v1.0
12 Gaur P, Sceusi EL, Samuel S, et al (2011). Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology, 141, 1728-37.   DOI
13 Huang EH, Hynes MJ, Zhang T, et al (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res, 69, 3382-9.   DOI
14 Ibrahim A, Khaled H, Mikhail N, et al (2014). Cancer incidence in Egypt, results of the national population-based cancer registry program. J Cancer Epidemiology.
15 Ieni A, Giuffre G, Adamo V, et al (2011). Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas. Anticancer Res, 31, 1315-20.
16 Jiang F, Qiu Q, Khanna A, et al (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res, 7, 330-8.   DOI
17 Keymoosi H, Gheytanchi E, Asgari M, et al (2014). ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev, 15, 2013-20.   DOI
18 Madjd Z, Ramezani B, Molanae S, et al (2012). High Expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev, 13, 2973-8.   DOI
19 Lamy PJ, Martin PM, Romieu G, et al (2013). Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for earlystage breast cancer, a systematic review. J Natl Cancer Inst, 105, 149.
20 Liao Y, Hu X, Huang X, et al (2010). Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biological & Pharmaceutical Bulletin, 33, 738-742.   DOI
21 Meacham C, and Morrison S (2013), Tumor heterogeneity and cancer cell plasticity. Nature, 501, 328-37.   DOI
22 Meyer M, Fleming J, Ali M, et al (2009). Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 11, R82.   DOI
23 Mills J, and Shivdasani R (2011). Gastric epithelial stem cells. Gastroenterology, 140, 412-24.   DOI
24 Morimoto K, Kim S, Tanei T, et al (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci, 100, 1062-8.   DOI
25 Navin N, Kendall J, Troge J, et al (2011). Tumor evolution inferred by single-cell sequencing. Nature, 472, 90-4.   DOI
26 Ohi Y, Umekita Y, Yoshioka T, et al (2011). Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology, 59, 776-80   DOI
27 Resetkova E, Reis-Filho J, Jain R, et al (2010). Prognostic impact of ALDH1 in breast cancer, a story of stem cells and tumor microenvironment. Breast Cancer Res Treat, 123, 97-108.   DOI
28 Park SY, Lee HE, Li H, et al (2010). Heterogeneity for stem cellrelated markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res, 16, 876-87.   DOI
29 Rao Q, Yao T, Zhang B, et al (2012). Expression and functional role of ALDH1 in cervical carcinoma cells. Asian Pac J Cancer Prev, 13, 1325-31.   DOI
30 Rasha M Abd El Atti, Riham M Abu-Zeid (2012). CD133 and FGF7. Egyptian Journal of Pathology, 32, 142-9.   DOI
31 Reya T, Morrison S, Clarke M, et al (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11.   DOI
32 Sakakibara M, Fujimori T, Miyoshi T, et al (2012). Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer. Cancer, 118, 3899-910.   DOI
33 Saricanbaz I, Karahacioglu E, Ekinci O, et al (2014). Prognostic significance of expression of CD133 and Ki-67 in gastric cancer. Asian Pac J Cancer Prev, 15, 8215-9.   DOI
34 Satpute P, Hazarey V, Ahmed R et al (2013). Cancer stem cells in head and neck squamous cell carcinoma, a review. Asian Pac J Cancer Prev, 14, 5579-87.   DOI
35 Schneider M, Huber J, Hadaschik B, et al (2012). Characterization of colon cancer cells, a functional approach characterizing CD133 as a potential stem cell marker," BMC Cancer, 12, 96.   DOI
36 Timothy E, Wang D, Harki D (2013). Cell surface markers of cancer stem cells, diagnostic macromolecules and targets for drug delivery. Drug Delivery and Translational Research, 3, 121-42.   DOI
37 Shi C, Tian R, Wang M, et al (2010). CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther, 10, 1182-90.   DOI
38 Shimada Y, Ishii G, Nagai K et al (2009). Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci, 100, 2054-9.   DOI
39 Tessari A, Palmieri D, Di Cosimo S (2013). Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers Med, 7, 1-19.
40 Tirino V, Camerlingo R, Franco R, et al (2009). The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg, 36, 446-53.   DOI
41 Turner N, Pestrin M, Galardi F, et al (2014). Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel), 6, 684-707.   DOI
42 Visvader J, and Lindeman G (2008). Cancer stem cells in solid tumours, Accumulating evidence and unresolved questions. Nat Rev Cancer, 8, 755-68.   DOI
43 Wang K, Liu L, Zhang T, et al (2011). Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomedicine, 6, 3207-18.
44 Wright M, Calcagno A, Salcido C, et al (2008). Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res, 10, 10.
45 Zobalova R, Prokopova K, Stantic M, et al (2011). The Potential role of CD133 in immune surveillance and apoptosis, a mitochondrial connection? Antioxidants & Redox Signaling, 15, 2989-3002.   DOI
46 Wu Y, and Wu P (2009). CD133 as a marker for cancer stem cells, progresses and concerns. Stem Cells Dev, 18, 1127-34.   DOI
47 Yan X, Ma L, Yi D, et al (2011). A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A, 108, 1591-6.   DOI
48 Zhao P, Lu Y, Jiang X, et al (2011). Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci, 102, 1107-11.   DOI